All analyses
AI analysis

Maskeliya Plantations Plc: research report

UndervaluedneutralSep 22, 2026

The evidence points to a neutral view: 5.2-times earnings are offset by an 11.7% June-quarter profit decline. A high dividend yield is the main counterweight.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why balanced

  • The shares trade at 5.2 times trailing earnings, placing MASK in the cheapest 5% of plantation peers on P/E.
  • Trailing return on equity was 20.4%, while the dividend yield is 6.5%.
  • MASK scores 93 out of 100 on price against book value, earnings and dividends across the CSE.

Against this. June-quarter net profit fell 11.7% year-on-year as operating margin narrowed to 13.8%.

Operating margin
13.8%sector 8.4%
from 15.3% a year earlier
Net margin
9.3%sector 4.3%
from 10.3% a year earlier, revenue -2.6%
Return on equity
20.4%
twelve months to Jun 30, 2026, unaudited
P/E
5.1sector 9.3
earnings Rs 11.83 per share
P/B
1.04sector 1.11
book Rs 57.87 per share
Dividend yield
6.67%sector 2.35%
33.8% of earnings paid out

Current figures, updated daily from filings to Jun 30, 2026. The report below was written on Sep 22, 2026. Sector figures are the median of 25 listed companies in the same sector.

Overview

Maskeliya Plantations operates tea estates and processing centres, with smaller exposure to timber, coffee, cinnamon and fruit. The latest June quarter was weaker than a year earlier: revenue, operating profit and net profit all declined, reversing some of the earnings momentum that supported the prior year, while the balance sheet remained equity-funded at the last audited year-end.

Price performance

The share closed at LKR 61.80 on 22 September 2026. It has fallen 38.6% over one year while the ASPI gained 1.5%, showing a substantial company-specific divergence over that period. At 7.6% of its 52-week range, it sits close to the year's low rather than its high; recent volatility is below its own one-year norm, while 20-day trading volume is above the 60-day norm.

The three-year record shows two falls of 15% or more, the deepest 50%, which has not yet recovered. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day (462% of it), making that order a large part of normal daily trading.

Valuation

At 5.2 times trailing earnings, a buyer pays about LKR 5.20 for each LKR 1 of the last twelve months' profit. This is in the cheapest 5% of plantation peers by P/E. P/B is 1.07 times, meaning the market price is close to the LKR 1 of net assets behind each share, while trailing ROE of 20.4% supports a valuation above book value.

The 6.5% dividend yield is high relative to the sector, although the recorded payout moved from LKR 4.50 for FY2025 to LKR 4.00 for FY2026; the latest year may still be incomplete. Against MASK's own record, the P/E is more expensive than 61% of days since February 2012. A buyer at this price is relying on earnings spread across the year rather than a single exceptional quarter: the latest quarter supplied 24.2% of trailing EPS, and its lower margin changes the P/E only to 5.1 times.

News and sentiment

Direct company coverage is thin, with no material articles in the past 90 days. The only recent item was the LKR 4.00 first interim dividend reported on 30 March; its ex-date was 10 April 2026, so a buyer today does not receive it.

Financials

June-quarter revenue fell 2.5% year-on-year and operating profit fell 12.4%, while net profit declined 11.7% to LKR 155 million. Gross margin was 17.6% versus 18.9% a year earlier, operating margin was 13.8% versus 15.3%, and net margin was 9.3% versus 10.3%. The operating-margin result was among the weakest of the last five comparable June quarters, so the profit a share represents was generated less efficiently than a year earlier.

Below-the-line costs took LKR 73.7 million from operating profit in the June quarter, though this drag was lower than a year earlier. Equity increased to LKR 3.1 billion from LKR 2.9 billion at the March year-end, and the share count remained about 54.0 million, so the year-on-year profit movement is not a mechanical per-share effect.

For the audited year ended March 2026, revenue rose 5.0% but net profit fell 31.3%. The twelve months to June 2026 produced LKR 7.0 billion of revenue and a 8.9% net margin, but these trailing figures are assembled from interim filings rather than an audited full year.

Risks

The leading risk is that weaker tea-sector output conditions and MASK's own thinner June margins coincide. High Grown tea output reached a 34-year monthly low in August amid heavy rain and cloud cover, according to sector reporting; this is sector context rather than company-specific production data, but tea is MASK's core business.

Funding risk appears contained at the last audited year-end, but working-capital discipline still matters. The current ratio was 1.45 times, meaning the company had LKR 1.45 of short-term assets, including stock and customer receivables, for each LKR 1 of bills due within a year. Operating cash flow equalled 0.81 times operating profit, so only about 81 cents of operating cash arrived for every rupee of reported operating profit. Interest cover was 10.62 times, indicating operating profit covered the finance bill more than ten times, and the March balance sheet held net cash.

Outlook

As at 22 September 2026, the next material event is the September interim-quarter filing, expected between 6 and 14 November. It will show whether the June decline in margins and profit persisted while tea-sector production conditions were weak, or whether the pressure was confined to that quarter. The available data cannot determine MASK's estate-level crop volumes, realised tea prices or the effect of recent weather before that filing.

About this report. Generated on Sep 22, 2026 from market data up to Sep 22, 2026, 0 material news articles over 90 days and financials to Jun 30, 2026, and scored 93 of 100 on value (undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports